Literature DB >> 7569508

Bayesian decision procedures for dose determining experiments.

J Whitehead1, H Brunier.   

Abstract

This paper describes the Bayesian decision procedure and illustrates the methodology through an application to dose determination in early phase clinical trials. The situation considered is quite specific: a fixed number of patients are available, to be treated one at a time, with the choice of dose for any patient requiring knowledge of the responses of all previous patients. A continuous range of possible doses is available. The prior beliefs about the dose-response relationship are of a particular form and the gain from investigation is measured in terms of statistical information gathered. How all of these specifications may be varied is discussed. A comparison with the continual reassessment method is made.

Entities:  

Mesh:

Year:  1995        PMID: 7569508     DOI: 10.1002/sim.4780140904

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  18 in total

Review 1.  Learning from previous responses in phase I dose-escalation studies.

Authors:  J Whitehead; Y Zhou; N Stallard; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

2.  Isotonic designs for phase I trials in partially ordered groups.

Authors:  Mark Conaway
Journal:  Clin Trials       Date:  2017-08-04       Impact factor: 2.486

3.  Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.

Authors:  Tze L Lai; Philip W Lavori
Journal:  Stat Biosci       Date:  2011-12

4.  Continual Reassessment and Related Dose-Finding Designs.

Authors:  John O'Quigley; Mark Conaway
Journal:  Stat Sci       Date:  2010       Impact factor: 2.901

5.  Incorporating individual and collective ethics into phase I cancer trial designs.

Authors:  Jay Bartroff; Tze Leung Lai
Journal:  Biometrics       Date:  2010-08-19       Impact factor: 2.571

6.  Stochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.

Authors:  Ying Kuen Cheung
Journal:  Stat Sci       Date:  2010-05       Impact factor: 2.901

7.  Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations.

Authors:  Richard F Potthoff; Stephen L George
Journal:  Stat Biopharm Res       Date:  2009-08-01       Impact factor: 1.452

8.  Dimension of model parameter space and operating characteristics in adaptive dose-finding studies.

Authors:  Alexia Iasonos; Nolan A Wages; Mark R Conaway; Ken Cheung; Ying Yuan; John O'Quigley
Journal:  Stat Med       Date:  2016-04-18       Impact factor: 2.373

9.  A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.

Authors:  Haitao Pan; Ying Yuan
Journal:  Stat Med       Date:  2016-03-16       Impact factor: 2.373

10.  A Phase I/II trial design when response is unobserved in subjects with dose-limiting toxicity.

Authors:  Thomas M Braun; Shan Kang; Jeremy Mg Taylor
Journal:  Stat Methods Med Res       Date:  2012-11-01       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.